share_log

10-K: FY2024 Annual Report

SEC ·  Feb 12 17:56

Summary by Futu AI

Bristol-Myers Squibb reported total revenues of $48.3 billion for fiscal year 2024, representing a 7% increase from $45.0 billion in 2023. Growth was driven by strong performance in the Growth Portfolio and Eliquis, partially offset by generic erosion in the Legacy Portfolio. U.S. revenues increased 9% to $34.1 billion while International revenues grew 1% to $13.2 billion.The company recorded a net loss of $8.9 billion in 2024 compared to net earnings of $8.0 billion in 2023, primarily due to a one-time, non-deductible Acquired IPRD charge of $12.1 billion from the Karuna acquisition. Research and development expenses increased 20% to $11.2 billion, reflecting higher drug development costs to support the broader portfolio and recent acquisitions.During 2024, BMS completed strategic acquisitions of Karuna ($14.0B), RayzeBio ($4.1B) and Mirati ($4.8B) to expand its portfolio. The company issued $13.0 billion in senior unsecured notes to partially fund these acquisitions. BMS also received multiple regulatory approvals including Cobenfy for schizophrenia and Opdivo Qvantig for multiple indications.
Bristol-Myers Squibb reported total revenues of $48.3 billion for fiscal year 2024, representing a 7% increase from $45.0 billion in 2023. Growth was driven by strong performance in the Growth Portfolio and Eliquis, partially offset by generic erosion in the Legacy Portfolio. U.S. revenues increased 9% to $34.1 billion while International revenues grew 1% to $13.2 billion.The company recorded a net loss of $8.9 billion in 2024 compared to net earnings of $8.0 billion in 2023, primarily due to a one-time, non-deductible Acquired IPRD charge of $12.1 billion from the Karuna acquisition. Research and development expenses increased 20% to $11.2 billion, reflecting higher drug development costs to support the broader portfolio and recent acquisitions.During 2024, BMS completed strategic acquisitions of Karuna ($14.0B), RayzeBio ($4.1B) and Mirati ($4.8B) to expand its portfolio. The company issued $13.0 billion in senior unsecured notes to partially fund these acquisitions. BMS also received multiple regulatory approvals including Cobenfy for schizophrenia and Opdivo Qvantig for multiple indications.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 365

Recommended